- Home
- NTRA vs ESS Comparison
NTRA vs ESS Comparison
Compare NTRA & ESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- ESS
- Stock Information
- Founded
- NTRA 2003
- ESS 1971
- Country
- NTRA United States
- ESS United States
- Employees
- NTRA N/A
- ESS N/A
- Industry
- NTRA Medical Specialities
- ESS Real Estate Investment Trusts
- Sector
- NTRA Health Care
- ESS Real Estate
- Exchange
- NTRA Nasdaq
- ESS Nasdaq
- Market Cap
- NTRA 20.9B
- ESS 17.9B
- IPO Year
- NTRA 2015
- ESS 1994
- Fundamental
- Price
- NTRA $151.95
- ESS $282.83
- Analyst Decision
- NTRA Strong Buy
- ESS Hold
- Analyst Count
- NTRA 17
- ESS 20
- Target Price
- NTRA $178.41
- ESS $306.22
- AVG Volume (30 Days)
- NTRA 1.1M
- ESS 447.2K
- Earning Date
- NTRA 05-08-2025
- ESS 04-29-2025
- Dividend Yield
- NTRA N/A
- ESS 3.63%
- EPS Growth
- NTRA N/A
- ESS 27.78
- EPS
- NTRA N/A
- ESS 10.45
- Revenue
- NTRA $1,831,000,000.00
- ESS $1,861,154,000.00
- Revenue This Year
- NTRA $15.45
- ESS $3.48
- Revenue Next Year
- NTRA $18.43
- ESS $4.03
- P/E Ratio
- NTRA N/A
- ESS $27.07
- Revenue Growth
- NTRA 51.50
- ESS 9.74
- 52 Week Low
- NTRA $92.14
- ESS $243.85
- 52 Week High
- NTRA $183.00
- ESS $317.73
- Technical
- Relative Strength Index (RSI)
- NTRA 49.96
- ESS 50.27
- Support Level
- NTRA $153.40
- ESS $283.72
- Resistance Level
- NTRA $159.15
- ESS $288.52
- Average True Range (ATR)
- NTRA 6.36
- ESS 6.06
- MACD
- NTRA 0.65
- ESS 1.44
- Stochastic Oscillator
- NTRA 39.44
- ESS 54.46
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 256 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.